Zobrazeno 1 - 10
of 78
pro vyhledávání: '"W Laughlin"'
Autor:
Kelly L. Drew, Saurav Bhowmick, Bernard W. Laughlin, Anna V. Goropashnaya, Øivind Tøien, M. Hoshi Sugiura, Ardy Wong, Kambiz Pourrezaei, Zeinab Barati, Chao-Yin Chen
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
Targeted temperature management (TTM) is standard of care for neonatal hypoxic ischemic encephalopathy (HIE). Prevention of fever, not excluding cooling core body temperature to 33°C, is standard of care for brain injury post cardiac arrest. Althoug
Externí odkaz:
https://doaj.org/article/0e64fe960aa641c1b9f01b4d3f6b762e
Publikováno v:
North American Journal of Fisheries Management. 40:1161-1173
Publikováno v:
Value in Health. 25:S349
Publikováno v:
North American Journal of Fisheries Management. 39:45-57
Autor:
Kelly L. Drew, Zeinab Barati, Isaac R. Bailey, Lucille A. Moore, Lori K. Bogren, Bernard W. Laughlin
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 362:424-430
Cardiac arrest is a leading cause of death in the United States, and, currently, therapeutic hypothermia, now called targeted temperature management (TTM), is the only recent treatment modality proven to increase survival rates and reduce morbidity f
Publikováno v:
River Research and Applications. 32:1808-1818
Insight into environments that contribute recruits to adult fish stocks in riverine systems is vital for effective population management and conservation. Catfishes are an important recreational species in the Mississippi River and are commercially h
Publikováno v:
Value in Health
Objectives: To develop a framework to compare integrated scientific advice (ISA) procedures, which are services available to companies to seek advice on a technology’s evidence generation plans from multiple stakeholders including regulators, healt
Publikováno v:
Value in Health. 23:S610
Autor:
Zeinab Barati, Isaac R. Bailey, Sarah A Rice, Bernard W. Laughlin, Lori K. Bogren, Kelly L. Drew
Targeted temperature management is standard of care for cardiac arrest and is in clinical trials for stroke. N(6)-cyclohexyladenosine (CHA), an A(1) adenosine receptor (A(1)AR) agonist, inhibits thermogenesis and induces onset of hibernation in hiber
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e147dc8d05ba43beaf1018c695c5a0de
https://europepmc.org/articles/PMC5994145/
https://europepmc.org/articles/PMC5994145/
Publikováno v:
The FASEB Journal. 32